Literature DB >> 14686737

Response of neoplastic meningitis from solid tumors to oral capecitabine.

Pierre Giglio1, Ivo W Tremont-Lukats, Morris D Groves.   

Abstract

Neoplastic meningitis (NM) is a major challenge for the neuro-oncologist as it constitutes a relatively common clinical problem in systemic and central nervous system cancers, and is very difficult to treat. NM portends a significant worsening in prognosis. Chemotherapeutic treatment options are limited, and not particularly effective. We report two cases of NM from breast carcinoma and a third with esophageal carcinoma, which responded to treatment with capecitabine, an oral prodrug for 5-flurouracil. We believe capecitabine warrants further investigation in patients with NM. In some patients, its use may result in clinical and radiographic tumor responses, improved quality of life, and possibly increased survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14686737     DOI: 10.1023/b:neon.0000003752.89814.ca

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

1.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

Review 2.  Leptomeningeal carcinomatosis.

Authors:  S A Grossman; M J Krabak
Journal:  Cancer Treat Rev       Date:  1999-04       Impact factor: 12.111

3.  Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate.

Authors:  D L Trump; S A Grossman; G Thompson; K Murray; M Wharam
Journal:  Cancer Treat Rep       Date:  1982-07

Review 4.  Capecitabine.

Authors:  M Dooley; K L Goa
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer.

Authors:  F J Esteva; L T Soh; F A Holmes; W Plunkett; C A Meyers; A D Forman; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  2000       Impact factor: 3.333

6.  Thymidine phosphorylase in human esophageal squamous cell carcinoma.

Authors:  Y Takebayashi; S Natsugoe; M Baba; S Akiba; T Fukumoto; K Miyadera; Y Yamada; S Takao; S Akiyama; T Aikou
Journal:  Cancer       Date:  1999-01-15       Impact factor: 6.860

7.  The prognostic significance of microvessel density and thymidine phosphorylase expression in squamous cell carcinoma of the esophagus.

Authors:  M Igarashi; D K Dhar; H Kubota; A Yamamoto; O El-Assal; N Nagasue
Journal:  Cancer       Date:  1998-04-01       Impact factor: 6.860

Review 8.  Capecitabine: a novel agent for the treatment of solid tumors.

Authors:  P G Johnston; S Kaye
Journal:  Anticancer Drugs       Date:  2001-09       Impact factor: 2.248

9.  Meningeal carcinomatosis in breast cancer.

Authors:  H Y Yap; B S Yap; C K Tashima; A DiStefano; G R Blumenschein
Journal:  Cancer       Date:  1978-07       Impact factor: 6.860

10.  Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase.

Authors:  M Kitazono; Y Takebayashi; K Ishitsuka; S Takao; A Tani; T Furukawa; K Miyadera; Y Yamada; T Aikou; S Akiyama
Journal:  Biochem Biophys Res Commun       Date:  1998-12-30       Impact factor: 3.575

View more
  12 in total

Review 1.  Leptomeningeal Carcinomatosis in Esophageal Cancer: Case Report and Review of Literature.

Authors:  Amardeep Singh Aulakh; Amanpreet Buttar; Bilal Piperdi
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Contrast-Enhancing Meningeal Lesions Are Associated with Longer Survival in Breast Cancer-Related Leptomeningeal Metastasis.

Authors:  Anne Constanze Regierer; Andrea Stroux; Dagmar Kühnhardt; Annette Dieing; Silvia Lehenbauer-Dehm; Bernd Flath; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2008-04-15       Impact factor: 2.860

Review 3.  Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approaches.

Authors:  Giuseppe Lombardi; Fable Zustovich; Patrizia Farina; Alessandro Della Puppa; Renzo Manara; Diego Cecchin; Antonella Brunello; Alessandro Cappetta; Vittorina Zagonel
Journal:  Oncologist       Date:  2011-07-27

Review 4.  Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Authors:  Ajay Dhakal; Amanda E D Van Swearingen; Ruth O'Regan; Carey K Anders
Journal:  Curr Treat Options Oncol       Date:  2022-09-22

5.  Prolonged regression of metastatic leptomeningeal breast cancer that has failed conventional therapy: a case report and review of the literature.

Authors:  Andrew Vincent; Glenn Lesser; Doris Brown; Tamara Vern-Gross; Linda Metheny-Barlow; Julia Lawrence; Michael Chan
Journal:  J Breast Cancer       Date:  2013-03-31       Impact factor: 3.588

6.  Treatment of leptomeningeal spread of NSCLC: a continuing challenge.

Authors:  Seema Nagpal; Jonathan Riess; Heather Wakelee
Journal:  Curr Treat Options Oncol       Date:  2012-12

7.  Capecitabine therapy of central nervous system metastases from breast cancer.

Authors:  Meltem Ekenel; Adilia M Hormigo; Scott Peak; Lisa M Deangelis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2007-07-05       Impact factor: 4.130

8.  Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

Authors:  Cyrus Chargari; Youlia M Kirova; Véronique Diéras; Pablo Castro Pena; Pablo Castro Pena; Francois Campana; Paul H Cottu; JeanYves Pierga; Alain Fourquet
Journal:  J Neurooncol       Date:  2009-01-25       Impact factor: 4.130

9.  Carcinomatous meningitis: Leptomeningeal metastases in solid tumors.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Surg Neurol Int       Date:  2013-05-02

10.  Breast cancer leptomeningeal metastasis: propensity of breast cancer subtypes for leptomeninges and the analysis of factors influencing survival.

Authors:  Anna Niwińska; Halina Rudnicka; Magdalena Murawska
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.